Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment-Reference-Cited by-同舟云学术

Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment

Published:2024-05-27 Issue:4 Volume:25 Page:685-688
ISSN:1175-0561
Container-title:American Journal of Clinical Dermatology
language:en
Short-container-title:Am J Clin Dermatol

Author:

Thomas Sarah E.^ORCID,Seyger Marieke M. B.,Mangnus Josje E.,Otero Marisol E.,Gostynski Antoni H.,Njoo Marcellus D.,Ossenkoppele Paul M.,Haeck Inge M.,Hendricksen-Roelofzen Judith H. J.,Körver John E. M.,Dodemont Sharon R. P.,Tupker Ron A.,Berends Maartje A. M.,Weppner-Parren Lizelotte M. J. T.,Keijsers Romy R. M. C.,Oostveen Annet M.,Peters Bas,Mommers Roland,van Doorn Martijn B. A.,Tjioe Milan,Veldkamp Wendelien R.,Kuijpers Astrid L. A.,Kleinpenning Marloes M.,de Jong Elke M. G. J.,van den Reek Juul M. P. A.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40257-024-00868-x.pdf

Reference5 articles.

1. Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30(7):1148–58. https://doi.org/10.1111/jdv.13611.

2. Bilal J, Berlinberg A, Bhattacharjee S, et al. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatolog Treat. 2018;29(6):569–78. https://doi.org/10.1080/09546634.2017.1422591.

3. Ghoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397(10275):754–66. https://doi.org/10.1016/s0140-6736(21)00184-7.

4. Kulig P, Musiol S, Freiberger SN, et al. IL-12 protects from psoriasiform skin inflammation. Nat Commun. 2016;7:13466. https://doi.org/10.1038/ncomms13466.

5. Zhou L, Wang Y, Wan Q, et al. A non-clinical comparative study of IL-23 antibodies in psoriasis. MAbs. 2021;13(1):1964420. https://doi.org/10.1080/19420862.2021.1964420.